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Introduction: Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease 
(ESRD), and 40% of patients with diabetes develop DKD. Although some pathophysiological 
mechanisms and drug targets of DKD have been described, the effectiveness or clinical 
usefulness of such treatment has not been well validated.  Therefore, searching for new targets 
and potential therapeutic candidates has become an emerging research area.  
Areas covered: The pathophysiological mechanisms, new drug targets and potential 
therapeutic compounds for DKD are addressed in this review.  
Expert opinion: Although preclinical and clinical evidence has shown some positive results 
for controlling DKD progression, treatment regimens have not been well developed to reduce 
the mortality in patients with DKD globally. Therefore, the discovery of new therapeutic targets 
and effective target-based drugs to achieve better and safe treatment is urgently required. 
Preclinical screening and clinical trials for such drugs are needed.  
Keywords: diabetic complications, diabetic nephropathy, drug discovery, endothelin receptor 
blockers, oxidative stress, renin-angiotensin-aldosterone system, SGLT-2 inhibitors  
Article highlights. 
• Diabetic kidney disease (DKD) is the single most common cause of chronic 
kidney disease (CKD) and end-stage renal disease (ESRD), which is 
clinically characterized by persistent albuminuria of 30-300mg/day. 
• Multiple pathophysiological mechanisms have been proposed; therefore, the 
treatment could be difficult with single-drug therapy. 
3 
 
• Current treatment of DKD is not able to stop its pathological progression 
completely and reduce mortality rate. Novel target discovery and therapeutic 
strategy development are urgently required. 
• This article mainly focuses on new potential drug targets and related new 
compounds for the potential treatment of DKD.   
The box summarizes key points contained in the article. 
 
1. Introduction  
Diabetic kidney disease (DKD), can be defined as diabetes with persistent 
microalbuminuria (ratio of urine albumin to creatinine ≥30mg/g) and impaired 
glomerular filtration rate (<60mL/min/1.73m2) leading to the deterioration of renal 
function and ultimately morbidity and mortality of patients1-3. Albuminuria is the 
characteristic clinical biomarker of DKD observed in patients with both type 1 and type 
2 diabetes mellitus (T1DM and T2DM). In 2013, the Global Burden of Disease Study 
reported a systematic analysis and estimated that the age-standardized mortality from 
DKD had increased by 106% compared to the year 19904. However, a recent study has 
found that DKD prevalence is not so stable and the death rate is increasing at the global 
level5. As the prevalence of both T1DM and T2DM patients is increasing, the incidence 
of macro- and microvascular complications, such as stroke, coronary heart disease, 
diabetic retinopathy, ischaemic nephropathy and kidney interstitial fibrosis, is also 
significantly increased6. The pathophysiological consequences of DKD under 
hyperglycaemia have been described in Figure 1. The current therapeutic strategy for 
DKD is to control proteinuria, hyperglycaemia, and high blood pressure to reduce 
cardiovascular and renal failure risk. Inhibition of the renin-angiotensin-aldosterone 
system (RAAS) and sodium-glucose cotransporter-2 (SGLT-2) has significant clinical 
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outcomes such as reduction in renal progression, all-cause mortality, proteinuria, and 
cardiovascular events7, 8. A clinical trial with empagliflozin (EMPA-KIDNEY (the 
study of heart and kidney protection with empagliflozin) is ongoing 
(WWW.ClinicalTrials.gov, Identifier: NCT03594110). These treatments are promising 
for  DKD; however, it is still proving difficult to halt the progression of DKD in patients  
mainly due to genetic and epigenetic variabilities6, 9. Therefore, development of new 
therapeutic strategies is required to target the underlying pathophysiological 
mechanisms. Some new drug targets have been recently identified, which could be 
helpful to develop new drugs to prevent renal and vascular damage in patients with 
DKD. Development of personalized medicine based on genetic and epigenetic 
variabilities could also be an approach to improve renal and cardiovascular outcomes 
in patients with DKD. In this review, we have covered recent advances in the 
pathophysiological mechanisms, potential new therapeutic targets and candidates for 
DKD. 
2. Pathophysiological mechanisms  
Multiple pathophysiological mechanisms are involved in the pathogenesis of DKD, 
including genetic and epigenetic aspects, abnormal renal haemodynamics, 
mitochondrial dysfunction and oxidative stress, ischaemia and inflammation, and 
podocyte injury and autophagy suppression. A schematic diagram for the mechanisms 
and possible drugs and their targets is shown in Figure 2.  
2.1. Genetic and epigenetic aspects of DKD development 
During the past 20 years, substantial evidence has been collected to understand the 
genetic basis of DKD in both T1DM and T2DM patients, such as familial clustering of 
DKD, the heritability and DKD -related traits, gene mapping for DKD in the genome-
wide association study (GWAS)10, 11. It has been found that not all diabetic patients 
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have developed DKD due to the difference in genetic susceptibility even though 
glycemia is not regularly controlled12. Due to the variation in genetic predisposition, 
the prevalence of DKD is higher in certain ethnic groups such as in native Americans, 
African Americans, and Mexican Americans than in other populations like European 
Americans10. The genes such as APOL1, RND3/RBM43, SLITRK3, ENPP7, and 
GNG7 make African American populations more prevalent to DKD10, 13. Identification 
of such risk genes is a direction for future personal medicine.   
The epigenetic modification including histone posttranslational modifications (PTMs), 
non-coding RNAs and methylation of DNA, may influence the development of DKD. 
Some pathologic conditions can modify the epigenetic profiles such as hyperglycaemia, 
hypoxia, inflammation, and release of some inflammatory cytokines9, 14, 15. The 
importance of DNA methylation on regulating DKD-related genes has been reported15, 
and the different degrees of DNA methylation has been demonstrated in T2DM patients 
with or without DKD16. The gene, UNC13B, has been reported to involve in the initial 
pathogenesis of DKD and cause apoptosis of glomerular cells in hyperglycaemic 
condition16, 17. The gene, RASALI, was found to be involved in hypermethylation, and 
therefore increased Ras activation in fibroblasts and led to tissue proliferation and 
fibrosis18. A case-control association study on blood-derived DNA from T1DM patients 
has revealed distinct methylation  patterns in genes which were related to mitochondrial 
function and confirmed the influence of  DNA methylation in DKD progression19. 
Epigenetic modifications in the kidneys of db/db T2DM diabetic mice have been well 
studied. Hypomethylation was reported for SGLT2, PCK1 and G6PC genes that 
capable of encoding proteins which involved in glucose metabolism as well as the gene 
that encodes hepatocyte nuclear factor 4 alpha (HNF4A), a transcription factor, which 
regulates transporters for reabsorption in the proximal tubule20. The persistence of 
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abnormal DNA methylation pattern was observed in  db/db mice  when pioglitazone 
was administered to reduce blood glucose levels and albuminuria, suggesting an 
important clue of epigenetic metabolic memory in the progression of DKD20. Histone 
methylation is also involved in the gene expression of transforming growth factor-beta 
1 (TGF-β1) mediated extracellular matrix (ECM)21. Applications of  histone 
deacetylase (HDAC)  inhibitors such as sodium butyrate, trichostatin, valproate and 
vorinostat in the streptozotocin (STZ)-induced diabetic rats have shown significant 
protective effects by decreasing proteinuria, glomerular injury, oxidative stress, 
fibrosis, and inflammation22-24. Furthermore, microRNAs (miRNAs) are abundantly 
expressed in the kidney. These small non-coding RNAs are involved in the degradation 
of mRNA and promote translation repression, which have been shown to affect DKD 
progressing25. In the early stage of DKD, an increased level of miRNA-192, a key gene 
regulator, was reported26. The induction of miRNA-192 in DKD was mediated by 
histone acetylation27. In mesangial cells, miRNA-192 up-regulates collagen type II 
(COLA2) and collagen type IV alpha 1 (COL4A1), and promotes the autoregulation of 
TGF-β1 by regulating other miRNAs and amplifying the response of p53 to TGF-β127-
29. Furthermore, miRNAs and long non-coding RNAs (lncRNAs) have been reported 
to play an essential role in the regulation of gene expression in DKD, such as the 
inhibition of lnc-MGC showed reduction of hypertrophy as well as glomerular 
extracellular matrix accumulation in diabetic mice30. Nuclear factor (erythroid-derived 
2)-like 2 (NRF2) is a transcription factor which is reported to have protective effects in 
diabetes by neutralizing reactive oxygen species (ROS) through the activation of the 
intracellular antioxidation systems and thus maintaining the balance of redox 
homeostasis31, 32, the inhibition of TGF-β1 and downregulation of cyclin-dependent 
kinase inhibitor 1A, and decrease of ECM production33. More studies are required to 
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understand the role of non-coding RNAs that could serve as molecular modulators in 
DKD. Collectively, these studies provide evidence that genetic difference and 
epigenetic modifications could explain the variability of drug responses and the 
molecular mechanisms involved in DKD progressing, which could pave the way for 
the development of personalized medicine. 
2.2. Abnormal renal haemodynamics  
Hyperfiltration by the glomeruli leads to the occurrence of DKD. Hyperglycaemia 
causes chronic metabolic and hemodynamic changes by modulating signalling 
pathways, transcription factors, cytokines, chemokines, and growth factors9, 13, 34, 35. It 
also leads to afferent arteriolar dilatation by increasing the release of vasoactive 
mediators, such as insulin-like growth factor 1 (IGF-1), glucagon, nitric oxide (NO), 
vascular endothelial growth factor (VEGF) and prostaglandins9. Due to the 
haemodynamic changes in diabetic patients, they may predispose DKD through both 
episodes of acute kidney injury and chronic progression36. Furthermore, upregulation 
of SGLT-2 in poorly glycaemic controlled diabetic patients was reported, which causes 
hyperfiltration of glucose as well as increased reabsorption of both glucose and sodium 
in proximal tubule37. Hence, a small amount of sodium reaches the macula densa, 
causing constriction of the afferent arteriole via tubuloglomerular feedback. 
Simultaneously, the efferent arteriole also constricts due to the high levels of 
angiotensin II (Ang II), causing glomerular hyperfiltration and hypertension38. 
Recently, it has been reported that Ang-II mediates MYH9 (a gene expressed in 
podocytes and involved in glomerular pathophysiology) downregulation that leads to 
podocyte structural and functional damage in DKD2. Ang-II also mediates transient 
receptor potential cation channel, subfamily C, member 6 (TRPC6) activation and 
reduces MYH9 expression2.Therefore, the Ang-II-mediated MYH9 depletion in DKD 
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increases the filtration barrier permeability by inducing apoptosis of podocyte via 
TRPC6 calcium channels and Ca2+ influx2. Hence, MYH9 could be regarded as a 
potential target for DKD. High oral intake of sodium also activates the RAAS system 
and causes blunting of the antihypertensive effects of angiotensin-converting enzyme 
inhibitors (ACEI) and angiotensin-II receptor blockers (ARB)2, 39-42. Aldosterone is also 
reported to be involved in the pathophysiology of DKD through plasminogen activator 
inhibitor 1 (PAI-1) and TGF-β promoting macrophage infiltration and renal tissue 
fibrosis43. 
Moreover, vascular homeostasis is regulated by endothelin-1 (ET-1), a potent 
vasoactive peptide produced by endothelial cells, via the activation of endothelin 
receptor. Compensatory high insulinaemia seen in T2DM increases ET-1 secretion 
resulting in vasoconstriction and vascular dysfunction44, 45. 
2.3. Mitochondrial dysfunction and oxidative stress 
Hyperglycaemia is thought to play an essential role in mitochondrial dysfunction 
through overloading the electron transport chain system that causes reduction of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) activity, estimulating excess 
ROS production, and  causes oxidative injury to podocytes and consequently their 
apoptosis46, 47. Excess ROS leads to deleterious effects on DNA, lipids and proteins and 
hence results in cell death, fibrosis, and eventual kidney dysfunction. Also, there is 
impairment of glycolytic metabolism that leads to accumulation of upstream glycolytic 
intermediates which shift the metabolic flux to other metabolic pathways (those are 
involved in kidney injury) such as polyol pathway, hexosamine pathway, activation of 
PKC and production of advanced glycation end products (AGEs) precursors relating to 
cellular dysfunction, DNA damage, vascular leakage, thrombosis, fibrosis, 
angiogenesis and inflammation46-48. It has been well investigated that hyperglycaemia 
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leads to upregulation of the polyol pathway. The glucose converted to sorbitol via the 
enzyme, aldose reductase and then the sorbitol is oxidised to fructose. The increase 
level of sorbitol leads to reduction of intracellular antioxidant, i.e. glutathione (GSH) 
which is thought to accelerate the intracellular oxidative stress and apoptosis. The 
fructose is the end product of the polyol pathway and increase of fructose concentration 
leads to inhibition of glycolysis. Fructose is also considered as a potential nephrotoxin. 
The endogenous production of fructose via the polyol pathway has led to the increased 
level of proteinuria, reduction of GFR, and increased of glomerular and proximal 
tubular injuries which have been investigated in a diabetic murine mice model. 
Furthermore, these mice also reported to express high levels of superoxide and 
inflammatory cytokine like NF-𝜅B6. On the other hand, it has been found that the DKD 
kidney contains fewer mitochondria, reduced mitochondrial superoxide formation, and 
therefore has reduced activity of electron chain complexes49. Stimulation of 
inflammatory processes via nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-kB) and vascular dysfunction was also identified due to the decreased 
mitochondrial superoxides that reduced the endothelial nitric oxide synthase (eNOS) 
phosphorylation process and AMP-activated protein kinase (AMPK) activity49. 
Hyperglycaemia and AGEs activate the RAAS system and induce renin and angiotensin 
expression in renal cells through kidney-specific G protein-coupled metabolic receptor 
GPR91 and ROS, causing deterioration of DKD. Ang-II stimulates the activation of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, chronic hypoxia, 
ROS production, inflammation, renal tissue fibrosis and renal tubular dysfunction and 
subsequent atrophy, and decrease of the number of small vessels2, 39, 41. Also, 
endothelial dysfunction due to the high glucose, insulinaemia and insulin resistance 
through intracellular mechanisms, relating to activation of  PKC, increased release of 
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ROS, and AGEs-induced proinflammatory signalling44. Activation of endothelin 
receptor A is also involved with podocyte injury, inflammation, oxidative stress, and 
fibrosis in the kidney44, 45. 
2.4. Ischaemia and inflammation 
Renal ischaemia and inflammation contribute to the pathophysiological progress of 
DKD. In developed DKD, the susceptibility of renal ischaemia is increased and this 
aggravates the renal inflammation by infiltration of neutrophils and macrophages in the 
kidney50. Renal medulla hypoxia occurs as the supply of oxygen is reduced due to 
glomerular and vascular lesions in DKD. Therefore, more ROS are generated and 
hypoxia-inducible factors (HIFs) are activated51. Along with this, intrarenal NO 
production is reduced52. Thus, the overproduction of ROS and hyperglycaemia lead to 
renal injury51, 52. Smoking also contributes to the progression of DKD in both T1DM 
and T2DM patients through upregulation of growth factors, escalating oxidative stress, 
and endothelial dysfunction53.  
In DKD, NF-kB is activated by phosphorylation and participates in the regulation of 
inflammatory factors. The activation of NF-kB is due to the increased levels of ROS 
and tumour necrosis factor (TNF). NF-kB is also involved in proteinuria and infiltration 
of renal interstitial inflammatory cells54. It has been reported that the immune system 
is also involved in the development of DKD55, 56. Diabetic kidney cells are prone to 
produce pro-inflammatory factors such as danger-associated molecular patterns 
(DAMPs), chemokines and cell adhesion molecules (CAMs) to facilitate innate 
immune responses. Hyperglycaemia increases the oxidized lipoproteins content, 
cellular stress, and activates macrophages, which disturb the functions of mitochondria 
and endoplasmic reticulum. Also, hyperglycaemia leads to abnormal activation of 
intracellular signalling pathways that are involved in the formation of immune 
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complexes. Deposition of these immune complexes in the kidney cells amplifies the 
innate immune response through the activation of complement and immunoglobulin 
Fcγ receptors
9, 57. It has further been reported that Janus-kinase signal transducer and 
activator of transcription (JAK-STAT) pathway is involved in the progression of DKD 
through angiotensin receptors, cytokines and chemokines with assist innate immune 
responses58. Recently, the involvement of gut microbiome in chronic inflammation with 
T2DM and CKD has been identified because of the release of toxin products such as 
indoxyl sulfate, cresyl sulfate and beta-2 microglobulin, by them into the blood which 
can trigger the activation of innate immune responses and cause systemic inflammation, 
which is thought to be associated with the pathophysiology of DKD59. 
2.5. Podocyte injury and autophagy suppression 
Podocyte injury plays an important role in the pathogenesis of DKD because it 
maintains the glomerular filtration barrier. The level of albuminuria is an early 
biomarker of the severity of DKD. There is evidence that a balance between the 
activation and repression of the WNT/β-catenin (CTNNB1) pathway is essential for 
podocyte health. The increased expression of CTNNB1 pathway components such as  
transcripts and proteins in podocytes has been reported in both humans and mice with 
DKD60, 61. In addition, some potential mechanisms such as RAAS (including ACE1 and 
ACE2), peroxisome proliferator-activated receptors (PPAR), prorenin and its receptor, 
AGEs, and their receptors (RAGE), ROS, prostanoids, adiponectin, and miRNAs have 
been reported for the irreversible podocyte injury and loss due to the contribution of 
diabetic milieu. Furthermore, some biomarkers that include podocyte-released 
microparticles and expression of podocyte-specific markers noticed in the urine of early 
podocyte injury have been identified62, 63, such as nephrin, a key structural and 
signalling molecule in the podocyte slit diaphragm64, 65. Recently, the involvement of 
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autophagy  in diabetic podocyte injuries has been reported, such as the two proteins, β-
arrestins and ubiquitin carboxy-terminal hydrolase 1 (UCH-L1), through the inhibition 
and upregulation of autophagy respectively66-69. Activated podocyte autophagy has 
protective effects on DKD through mammalian target of rapamycin (mTOR) regulation 
and autophagy-related (Atg) protein conjugation system; however, activation of mTOR 
suppresses autophagy69. Podocyte injury and autophagy are important targets to limit 
DKD progression because it has been identified that modulation of autophagic 
pathways in podocytes has shown promising results in the treatment of DKD patients. 
Autophagy activators such as metformin, resveratrol, 5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside (AMPK activators), rapamycin and sirtuin-
1(mTORC1 inhibitors) have been reported  as showing significant protective effects on 
renal structural integrity and function, and decrease albuminuria in experimental DKD 
models70. Similarly, selective apoptosis signal-regulating kinase (ASK1) inhibitor such 
as selonsertib has shown to reduce the rate of eGFR decline by 71% in phase 2 clinical 
trial in adult T2DM patients with moderate-to-advanced DKD. Selonsertib at oral daily 
doses of 2, 6, or 18 mg  was found to be safe with no dose-dependent adverse effects 
and considered to be able to slow DKD progression71. Recently, resveratrol (a non-
flavonoid polyphenol) has shown protective effects against podocyte apoptosis by 
stimulating autophagy, and astragaloside IV (the active component in a traditional 
Chinese herbal remedy) has also been shown to promote autophagy in podocyte and to 
attenuate endoplasmic reticulum (ER) stress in diabetic mice models with DKD72, 73. 
These data will allow researchers to expand the discovery of targets susceptible to 
pharmacological manipulation and compound screening via targeting podocyte injury 
and activation of autophagy. 
3. Therapeutic candidates and drug development for DKD  
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Current clinically used therapeutic drugs have shown some therapeutic efficacy for 
DKD, but they are unable to halt progression of the disease and stop death of patients13. 
Hence, many potential therapeutic targets have been explored in order to search 
alternate safe and effective therapeutic candidates. Several drug discovery programmes, 
such as preclinical small molecule screening (both natural and synthetic compounds) 
using cellular and animal models, and clinical trials on existing drugs, have been 
developed. The therapeutic target-based drugs used clinically (Table 1), and list of 
compounds in preclinical development (Table 2) for the treatment of DKD are 
summarized. 
3.1. RAAS inhibitors 
Over the last two decades, RAAS inhibitors have been the first-line treatment choice 
due to their successful clinical results13. Clinical trials on ACE inhibitors, such as 
captopril, and ARBs, including losartan and irbesartan, have demonstrated positive 
outcomes in decreasing albuminuria in DKD patients74-77. However, it has been 
reported that in clinical trials paricalcitol fails to show a renoprotective effect78. 
RAAS inhibitors have been shown to merely slow the progression of DKD, and some 
diabetic patients have still progressed to CKD and ESRD13. Inclusion of a 
mineralocorticoid receptor (MR) antagonist with ACE or ARB inhibitor regimen is 
beneficial in decreasing albuminuria, inflammation, and kidney fibrosis in patients 
with DKD. The risk of hyperkalaemia due to MR antagonists can be lowered using 
novel non-steroidal MR antagonist such as finerenone, which is an MR antagonist.  
Recent trials with finerenone showed reductions in proteinuria, kidney failure and 
DKD progression79. In another clinical trial, finerenone also showed to reduce 
cardiovascular mortality and morbidity in DKD patients80. Some other MR antagonist 
such as spironolactone has been tested in combination with antidiabetic/ 
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renoprotective/antihypertensive drugs which showed positive results in reducing 
DKD progression and lowering proteinuria81. The finerenone is still under phase 3 
clinical trial with T2DM patients to evaluate its efficacy in long-term for DKD82. 
Therefore, further investigation is still required to find better therapeutic candidates 
for this class of drug.  
3.2. SGLT-2 inhibitors 
SGLT-2 inhibitors are currently considered as the best therapeutic option for the 
treatment of DKD as this class of drugs have been shown to slow the progression 
of DKD by preventing glucose reabsorption at the proximal tubule of the kidney, 
and therefore lower the blood glucose levels in diabetic patients38. SGLT-2 
inhibitors, such as canagliflozin, dapagliflozin and empagliflozin, have shown 
renoprotective effects in clinical trials83.The mechanisms for renoprotection in 
T1DM and T2DM patients for SGLT-2 inhibitors could be due to the reduction of 
hyperfiltration and post-glomerular vasodilation83, 84. In addition, SGLT-2 
inhibitors have been shown to exhibit antioxidant and anti-inflammatory effects, 
and downregulate RAGE expression in DKD patients84. Canagliflozin has been 
shown to reduce the levels of matrix metalloproteinase-7, fibronectin-1, tumour 
necrosis factor receptor 1 (TNFR1) and interleukin-6 (IL-6) to protect the kidney85. 
Dapagliflozin also had protection against proteinuria, podocyte loss and glomerular 
injury in DKD86. The renoprotective effects of lusogliflozin in an ischemia-
reperfusion injury model was thought to be  due to lowering hypoxia by increasing 
the VEGF-A level and decreasing capillary rarefaction87. The renoprotective effects 
of SGLT-2 inhibitors is also considered to be due to the increase of erythropoietin 
production and reduction of diuretic requirement, as a result by lowering 
hypertension, increasing renal perfusion and oxygenation87. Hence, the role of 
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SGLT-2 inhibitors as renoprotectors can provide critical mechanistic insights into 
the use of these class of drugs for treating DKD. Recent clinical trials on SGLT-2 
inhibitors in the treatment of DKD have shown exciting results: 1) Empagliflozin 
has been shown to induce a 44% decrease in the risk of incidence or to worsen of 
nephropathy along with beneficial cardiovascular effects in DKD patients; 2) 
Canagliflozin (100 mg daily) treatment in T2DM patients has been shown to 
decrease 30% risk of ESRD; 3) Dapagliflozin has been shown to reduce 46% in 
sustained eGFR decline and to reduce ESRD risk or renal death, and shows 
cardiovascular protection88-90. Therefore, the clinical use of SGLT-2 inhibitors is 
currently a good option for the treatment of DKD. 
3.3. Endothelin receptor blockers 
Selective endothelin receptor A (ETA) blockers have shown some promising results 
by decreasing albuminuria, hypertension, fibrosis, structural injury, and the 
maintenance of podocyte integrity in experimental models of DKD, and therefore, 
blockage of ETA has become an attractive line of approach for the treatment of 
DKD. Currently, atrasentan, a selective ETA antagonist, is in phase III clinical 
trials. Atrasentan has  an antialbuminuric effect which may be due to the possible 
mechanism of restoring glomerular endothelial glycocalyx barrier and improving 
endothelial function,  which were  confirmed by the increase of NO concentrations, 
the decrease of glomerular heparinase expression and inflammation91. However, 
despite a 40% decrease in albuminuria, clinical studies on avosentan in combination 
with RAAS blockers for DKD has been terminated early due to high rates of 
cardiovascular adverse effects. These included edema, heart failure and 
cardiovascular deaths, which was thought to be due to high dose of avosentan that 
blocks both ETA and the endothelin receptor B (ETB)92. Therefore, it may be 
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assumed that selective inhibitors of ETA could be a potential approach for DKD 
treatment.  
3.4. New targets and drug development 
3.4.1. PKC inhibitors 
Protein kinase C (PKC) inhibitors have shown some promising results in DKD 
treatment93, 94. Ruboxistaurin, a selective PKC-β inhibitor, decreases albuminuria 
and improves renal function, and this was thought to be due to the prevention of 
TGF-β signalling upregulation in the STZ-induced DKD model93. In clinical trial 
results,  ruboxistaurin decreased albuminuria and increased eGFR in patients with 
DKD94. Moreover, the use of recombinant human GLP-1 has been reported 
showing protective effects in diabetic rats, which were thought to be mediated by 
partial PKC inhibition and PKA activation95. Therefore, development of novel PKC 
inhibitors could be a potential way to treat DKD. 
3.4.2. WNT signalling pathway inhibitors  
The wingless-type MMTV integration site (WNT) pathway involves in multiple 
physiological and pathological processes, such as angiogenesis, inflammation, and 
fibrosis. This signalling pathway also plays an important role in the pathogenesis of 
DN96. It has been shown that WNT pathway is activated in the kidneys of both 
T1DM and T2DM mice models. WNT signalling pathway inhibitors have been 
shown to decrease renal inflammation, fibrosis, and proteinuria in an Akita diabetic 
mice model. The blockade on the WNT pathway with the monoclonal antibody 2F1, 
which binds the ligand-binding domain of low density lipoprotein-receptor-related 
protein 6, has been shown to decrease proteinuria and renal fibrosis in both in db/db 
mice and STZ-induced T1DM rats96. Therefore, the WNT signalling pathway could 
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be a potential therapeutic target for DKD and inhibitors of the WNT pathway could 
provide useful new drug candidates. 
3.4.3. GLP-1 receptor agonists and DPP-4 inhibitors 
Two incretin hormones, glucagon-like peptide 1 (GLP-1) and gastric inhibitory 
peptide (GIP), are secreted from the intestine in response to food intake. This 
process can stimulate the secretion of insulin and maintains the homeostasis of 
glucose. Both peptides act on the GLP-1 receptor and decrease the concentration of 
glucose. However, dipeptidyl peptidase-4 (DPP-4), a proteolytic enzyme, rapidly 
degrades these peptides, so they exhibit a very short half-life (<2 mins). In T2DM 
patients, low GLP-1 levels have been reported, but patients with DKD have 
upregulated expression of DPP-4 in the glomeruli97, 98. Therefore, both GLP-1 
receptor agonists and DPP-4 inhibitors have been developed to control glycemia. 
These classes of compounds are also reported to show nephroprotective effects and 
to maintain renal functions. Exedin-4, a GLP-1 analogue, is reported to decrease 
albuminuria, glomerular hypertrophy, mesangial expansion, collagen 
accumulation, inflammatory infiltration, and the number of apoptotic cells in the 
glomeruli in type 2 diabetic mouse model with DKD99. Liraglutide has also been 
reported to alter the proteome of diabetic kidney and increases the levels of the Na+-
H+ antiporter 3 regulatory cofactor-2 protein and normalizes the peroxiredoxin-2 
levels100. Linagliptin, a DPP-4 inhibitor has been reported to decrease the kidney 
fibrosis in STZ-induced diabetic mouse model101. Similarly, sitagliptin has been 
shown to attenuate DKD and inhibited the TGF-β1 expression102. More studies are 
required on the two classes of compounds for DKD treatment. 
 
3.4.4. RAGE blockers 
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Some RAGE blockers, such as OPB-9195, LR-90, ALT-946 and pyridoxamine, 
have been tested in DKD models and have shown some beneficial effects both in 
animal models and clinical trials. The results include: 1) Pyridoxamine has been 
reported to improve the creatinine levels in DKD patients13; 2) RAGE-aptamer has 
beneficial effects in animal models of DKD103; 3) Pimagedine did not show any 
significant benefit in DKD with T1DM patients as it decreased the glomerular 
filtration rate very slowly, and at a higher dose (>300mg) caused glomerulonephritis 
103, 104. Therefore, more study is needed to evaluate the safety and potential 
therapeutic value for RAGE blockers. 
3.4.5. MCP-1, JAK and phosphodiesterase inhibitors targeting inflammation 
Inhibitors of the monocyte chemotactic protein-1 (MCP-1, also named CCL2) that  
can either neutralize the antibodies or antagonize the receptor (CCR2) have been 
shown to reduce albuminuria, kidney injury and inflammation in rodent models of 
DKD105. In phase II clinical trial, emapticap pegol, a CCL2 inhibitor, caused a 29% 
reduction in albuminuria106. Similarly, the Janus kinase 1 and 2 (JAK1 and JAK2) 
inhibitor baricitinib, in  phase II randomized control trial on T2DM patients, has 
been shown to reduce albuminuria by 40% relative to placebo107.  
Patients with DKD have a high serum level of TNF-α, an inflammatory mediator, 
which causes progression of the disease through inflammatory pathways. As a 
result, pentoxifylline, a phosphodiesterase inhibitor, was selected for a clinical trial 
on the basis that it has anti-inflammatory properties including the ability to lower 
TNF-α levels. Pentoxifylline was also reported to have ability to downregulate the 
effect of other inflammatory mediators, such as interferon-gamma, interleukin-1, 
IL-6, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1108-
111. Additionally, it has been reported that pentoxifylline in combination with 
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angiotensin II receptor blockers had an additive antiproteinuric effect in T2D 
patients112. Clinical evidence on anti-inflammatory agents belonging to all three 
being MCP-1, JAK and phosphodiesterase inhibitors class of drugs have shown to 
be safe and effective in the reduction of albuminuria in the treatment of DKD106, 107, 
112. Therefore, new potential selective anti-inflammatory agents could be developed 
for improved outcomes for DKD patients. 
3.4.6. Antioxidants targeting mitochondrial dysfunction 
Based on the pathophysiological mechanisms involved in the generation of excess 
free radicals, and subsequent oxidative stress due to the mitochondrial dysfunction, 
antioxidants may play an essential role in halting the progression of DKD. This 
provided a potential rationale to evaluate both natural and synthetic antioxidants in 
DKD models or clinical trials113. Clinical evidence revealed that SGLT-2 inhibitors 
exhibiting antioxidant and anti-inflammatory effects have renoprotective activity in 
DKD patients114. Similarly, DPP-4 inhibitors have also shown to protect the kidney 
by stimulating antioxidant defence systems and inhibiting fibrosis102. Mitoquinone 
(MitoQ), a well-known antioxidant targeting the mitochondria, has been tested and 
shown to prevent kidney injury, and to reduce albuminuria in db/db mice with DKD, 
by improving mitochondrial structural appearance and function as well as 
facilitating the mitophagy of defective mitochondria115. Genetic, modification or 
pharmacological inhibition of NADPH subunit Nox4 has shown significant 
renoprotection in T1DM mouse models116. In diabetic mice, the glutathione 
peroxidase (GPX) mimic, ebselen, reduced the oxidative stress and attenuated 
diabetes-associated renal injury117. Several other antioxidants, such as ascorbic 
acid, resveratrol, and ubiquinone have been tested in the context of DKD, which 
have shown potential therapeutic benefits in animal models and DKD patients72, 118. 
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Furthermore, the so-called “third gasotransmitter”, hydrogen sulfide (H2S), 
possessing antioxidant properties, has been tested in several DKD models. Evidence 
shows that H2S is produced in large amount in the kidney and the enzymes 
responsible for its production are expressed in the glomeruli, proximal and distal 
tubules, and interlobular arteries. On the contrary, it has also been identified that 
H2S production is low in DKD patients
119. The H2S supplementation has been 
shown to reduce oxidative stress and inflammation in the STZ-induced diabetic rats 
120. It has also been found that H2S can activate antioxidant defence mechanisms by 
increasing the SOD activities, the expression of NRF2 transcription factor, and by 
inhibiting pro-inflammatory and profibrotic pathways121. Therefore, H2S donors, 
such as NaSH (sodium hydrogen sulfide), have been tested in experimental DKD 
models and reported to show promising results including reduction of albuminuria 
and oxidative stress, inhibition of RAAS products, and renal fibrosis, and 
improvement of kidney function and glomerular filtration barrier122, 123. Therefore, 
H2S and its analogues can be deployed in new potential drug development. Taken 
together, the development of new potential antioxidants could be a good approach 
for treating DKD. 
3.4.7. Targeting ORAI and TRPC channels 
The underlying molecular mechanism of impaired albumin reabsorption in DKD 
has been studied124-127. It has been reported that ORAI1-3 are well expressed in 
proximal tubular epithelial cells (PTECs) and downregulated in the late stage of 
patients with DKD. Hyperglycaemia or blockade of insulin signalling reduced 
ORAI1-3 expression.  In addition, albumin uptake is impaired due to the inhibition 
of ORAI channels by both BTP2 ([N-{4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-
yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide]) and diethylstilbestrol, or 
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due to the silencing of ORAI expression124. In a transgenic mouse model, an 
increase in albuminuria was noticed due to the expression of a dominant-negative 
ORAI1 mutant (E108Q). The process of albumin endocytosis is Ca2+ dependent and 
accompanied by ORAI1 internalization. Furthermore, it has been shown that 
amnionless (AMN) was associated with ORAIs and forms STIM/ORAI/AMN 
complexes after Ca2+ store depletion. These mechanisms for protein reabsorption 
could be potential targets for the treatment of diabetic proteinuria124. It has also 
been found that mibefradil, a T-type Ca2+ channel antagonist, blocks ORAI 
channels in a dose-dependent manner by acting at the extracellular surface (IC50 
= 52.6 μM, 14.1 μM and 3.8 μM for ORAI1, ORAI2, and ORAI3, respectively). 
Application of mibefradil at more than 20 μM concentration inhibited Ca2+ 
release but did not affect cytosolic STIM1 translocation. Mibefradil inhibited 
cell proliferation, arrested cell cycle progression and induced apoptosis , and 
these pharmacological actions were due linked to its interaction with ORAI 
channels125. ORAI store-operated channels were also blocked by 4-chloro-3-
ethylphenol (4-CEP), an agonist of the ryanodine receptor (RyR), via direct 
ORAI1-3 channel inhibition. 4-CEP also caused indirect interference with STIM1 
subplasmalemmal translocation and clustering after store depletion126. To 
understand the roles of ORAI and STIM in vascular endothelial cells in diabetic 
conditions, it has been found, using tissue from patients, in vivo diabetic mice and 
in vitro cell models, that hyperglycaemia (25 mM D-glucose) enhanced the store-
operated Ca2+ entry through upregulation of ORAI/STIM via calcineurin-NFAT 
signalling. It was concluded that the pathway of upregulation of STIM/ORAI 
through Ca2+-calcineurin-NFAT is a novel mechanism to cause abnormal Ca2+ 
homeostasis and endothelial dysfunction in hyperglycaemia127. TRPC channels are 
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Ca2+ permeable cationic channels and TRPC6 is related to kidney disease. In 
podocytes, TRPC6 can bind and activate calpains, which are calcium-dependent 
cysteine proteases that control the podocyte cytoskeleton, cell adhesion, and 
motility via cleavage of paxillin, focal adhesion kinase, and talin. Therefore, TRPC6 
plays a scaffolding role in podocytes and thus affects the glomerular filter128. In 
addition, the TRPC5 channel was found to be activated by extracellular 
thioredoxin and interacted with  TRPC1 to form heteromultimeric channels, and 
both isoforms were present in the kidney and vasculatures129. Hence, both 
ORAIs and TRPC channels are worthy of further exploration to understand 
better their roles in DKD, and their potential as new therapeutic targets. 
4. Conclusion 
It can be concluded that RAAS inhibitors and SGLT-2 inhibitors are beneficial for 
DKD patients, but are not able to stop DKD progression completely. SGLT-2 
inhibitors possess both antioxidative and anti-inflammatory properties, which 
could be beneficial in terms of pathogenesis of DKD, and further SGLT-2 
inhibitors need to be developed. Additionally, SGLT-2 inhibitors such as 
canagliflozin, dapagliflozin and empagliflozin have shown potential effects at 
multiple molecular targets or contributors of DKD. Therefore, it is a good 
indication for the discovery and development of better future therapeutics for the 
treatment of DKD considering these SGLT-2 inhibitors as standard in experimental 
models. Furthermore, potential SGLT-2 inhibitors can be designed and synthesized 
for biological testing. Some new therapeutic targets such as DPP-4, PKC, JAK, 
endothelin receptor, ORAIs/TRPCs, etc  are involved in the pathological 
progression of DKD, and the development of inhibitors of these targets needs more 
investigation to validate their efficacy and safety before clinical applications.  
Furthermore, targeting renal circulation could be an alternative approach for DKD. 
For example, a combination of sacubitril and valsartan is under clinical trial phase 
III for DKD1, Cinaciguat, a soluble guanylate cyclase (sGC) activator has shown 
promising preclinical results, and rosiglitazone, a PPARγ activator has been shown 
to reduce both microalbuminuria and blood pressure in T2DM patients 
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independently of glycaemia130. Long-term use of epalrestat, an aldose reductase 
inhibitor, on T2DM patients has shown some potential usefulness on renal 
functions131. Overall, there remains an urgent need for identification and validation 
of new drug targets and candidates to achieve better treatment of DKD. 
5. Expert opinion 
RAAS and SGLT-2 inhibitors have been used clinically to treat DKD. These 
current standard treatments control hyperglycaemia, high blood pressure, lipid 
profile etc. to manage the disease, but are not sufficient to stop the disease 
progression. Many new therapies for DKD (DPP-4 inhibitor-ARBs, GLP-1R 
agonists, DPP-4 inhibitors, paricalcitol, pentoxifylline, pyridoxamine, 
ruboxistaurin, soludexide, thiazolidinediones, non-steroidal mineralocorticoid 
receptor antagonists and JAK inhibitors) have or are being preclinically and 
clinically tested in order to find new effective regimens. Recently, from clinical 
trials, meta-analysis on efficacy and safety risks of dual blockade of the RAAS in 
DKD has shown that dual inhibition therapy was superior to monotherapy in 
controlling blood pressure and reducing proteinuria. However, this analysis did not 
translate into long-term improvements including reduction of ESRD progression, 
cardiovascular mortality, and all-cause mortality. This study concluded that a 
combination of ACEI and ARB or direct renin inhibitor and ACEI/ARB may be a 
safe and effective therapy for patients with DKD, and a combination therapy may 
be more suitable for patients with DKD and in controlling hypertension and 
microalbuminuria. Therefore, this study reveals that use of dual therapy is tolerable 
in terms of safety risks of drugs and can be better employed in DKD treatment and 
more investigation is needed for new drug discovery. However, recent reports have 
also brought into focus the need for identification of more specific biomarkers to 
better understand the detailed pathophysiological mechanisms of DKD, and hence, 
to discover potential therapeutic agents for better future treatment and management 
of DKD. The specific biomarker discovery may identify the pathway (s) involved 
in the DKD progression and therefore, target based either mono or multi therapy 
could be prescribed to treat DKD patient subpopulations and can decrease the 
mortality rate. Due to the multiple pathophysiological mechanisms of DKD, it may 
be difficult to treat DKD by single-drug therapy, and so different target-based drug 
discovery approaches are being sought. It may also be thought that DKD might 
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progress to ESRD through nonalbuminuric pathways (can be defined as 
‘nonalbuminuric renal impairment’), which can be possibly treated by potential 
antioxidants or anti-inflammatory agents. Considering the importance and 
potentiality, use of SGLT-2 inhibitors could be a good option.  Some recent 
research investigations have helped to understand the role and importance of Ca2+ 
channels, such as ORAIs and TRPC, and their association with podocyte injury or 
renal artery circulation in DKD. This exploration should be continued in order to 
find new effective drug candidates via high throughput screening. The successful 
preclinical results of resveratrol and astragaloside IV on podocyte and animal 
models of DKD may motivate researchers to search for different classes of natural 
products. In addition, natural and synthetic antioxidants with potential free radical 
scavenging abilities, including H2S donor compounds, could also become 
candidates for DKD therapeutics.  
 
In summary, the genomic and epigenetic diversity and interplay of heterogeneous 
multiple pathophysiological mechanisms during the disease development makes 
the disease much more complex. Therefore, for effective treatment of DKD, novel 
targets need to be validated urgently so that discovery of new therapeutic drug 
candidates can be identified. 
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Table 1. List of therapeutic drugs with clinical trials for DKD 
Name and 
References 









                   





RAAS inhibition Clinically 




























































































































*Both drugs have tested clinically in combination form as LCZ696. 
RAAS: renin angiotensin aldosterone system; SGLT2: sodium glucose cotransporter 2; DPP-
4: dipeptidyl peptidase-4; AGE: advanced glycation end products; ETA: endothelin receptor 
A; PKC: Protein kinase C; JAK: Janus kinase; NEP: neprilysin; NRF2: Nuclear factor 
(erythroid-derived 2)-like 2; NF-kB: nuclear factor kB; TGF: transforming growth factor.  
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Table 2. List of compounds in preclinical development for the treatment of DKD. 
Name and  
References 
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HDAC: histone deacetylase; ER: endoplasmic reticulum; RAAS: renin angiotensin aldosterone 























Figure 1. The pathological consequences of hyperglycaemia in DKD. RAAS: renin 



























Figure 2. A schematic diagram describing the pathophysiological mechanisms of DKD 
and the novel therapeutic approach for its treatment. HDAC: histone deacetylases; 
RAAS: renin angiotensin aldosterone system; SGLT2: sodium glucose cotransporter 2; 
MR: mineralocorticoid receptor; ETA: endothelin receptor A; PKC: Protein kinase C; 
AGE: advanced glycation end products; DPP-4: dipeptidyl peptidase-4; JAK: Janus 
kinase; GLP-1: glucagon-like peptide-1. 
 
